How GLP-1s elevated Hims — and brought it back down to earth
Here’s a look at how the company’s GLP-1 business has sent the stock on a wild ride.
Hims & Hers executives spent much of its Monday earnings report assuring investors that the company is more than knockoff weight-loss drugs, a product line that has stimulated growth in recent years but also stirred legal troubles recently.
The majority of its revenue is from non-GLP-1 offerings, the company said in its shareholder letter. Only a “small minority” of its 2.5 million subscribers are taking compounded GLP-1s, CEO Andrew Dudum told analysts.
The company does not break down its sales by treatment segment. The last GLP-1 sales figure it gave was in Q2 2025, which showed that GLP-1s made up $420 million of its $1.1 billion in sales for the first half of 2025, or about 38%.
“Hims & Hers has always been and continues to be more than one treatment,” Dudum said Monday.
But buried in its annual report, the company disclosed that it is under investigation by Securities and Exchange Commission. The agency asked it to “preserve certain documents and information concerning the Company’s public statements and disclosures regarding compounded semaglutide and related business relationships.”
That only adds to Hims’ legal troubles: it is facing a patent infringement lawsuit from Novo Nordisk, the drugmaker that makes the weight-loss drugs Hims sells knockoffs of, and a potential inquiry by the Department of Justice.
While the company sees more diverse revenue streams, the market doesn’t seem convinced. The stock is down more than 50% for the year and is trading at just about $1 more than it was before the company announced that it would sell GLP-1s.
Here’s a look at how the company’s GLP-1 business has sent the stock on a wild ride:
